Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06992882RecruitingPhase 3
Comparing two chemo regimens with Herceptin for early breast cancer
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05761223RecruitingPhase 1/Phase 2
Study of FB849 for adults with measurable cancer lesions
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Cleveland, OhioAges 18 years+ - NCT07426757RecruitingPhase 1
A study of PF-07994525 for advanced multiple myeloma
This trial tests an experimental drug, PF-07994525, for people with advanced multiple myeloma that has not responded to or could not tolerate at least 3 prior treatments. The goal is to see if it can help control the cancer.
Coral Gables, FloridaAges 18 years+ - NCT06668584RecruitingPhase 2
Olutasidenib to prevent cancer return after stem cell transplant
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
Houston, TexasAges 18–75 - NCT07120191Recruiting
My Connect Post-Op study for joint replacement patients
This trial tests a smartphone tool to help communicate with your care team after knee or hip replacement surgery. It aims to improve your recovery experience.
Wichita, KansasAges 22–80 - NCT07449702RecruitingPhase 2
Long-term safety study of ORKA-001 for plaque psoriasis
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
Fountain Valley, CaliforniaAges 18 years+ - NCT06636552RecruitingPhase 2
Alternating drug combo plus daratumumab for newly diagnosed plasma cell leukemia
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
Athens, AtticaAges 18–80 - NCT06879938Recruiting
Hyaluronic Acid and Oxygen Therapy for Menopause Symptoms
This trial tests a combination of a vaginal gel (hyaluronic acid) and a special oxygen device for women experiencing vaginal dryness and discomfort due to menopause, including those with a history of breast cancer. It aims to see if this treatment can improve symptoms better than standard care.
Pavia, PaviaAges 18 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT05868876RecruitingPhase 1
Testing AK127 plus AK104 for advanced cancers
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT06857305Enrolling by invitationPhase 3
Eribulin every two weeks vs standard schedule for advanced breast cancer
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
Beijing, BAges 18 years+ - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07053904Enrolling by invitationPhase 1
Study of two experimental cancer drugs for advanced solid tumors
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
New Taipei CityAges 18 years+ - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Fayetteville, ArkansasAges 18–100 - NCT07347080RecruitingEarly Phase 1
Study of a new RNA-based drug for type 2 diabetes
This trial tests an experimental injection (CR059) for type 2 diabetes. It looks at safety and how the body handles different doses. You may qualify if you have had diabetes for 3 months to 5 years and are currently managing it with diet/exercise or certain diabetes pills.
Luoyang, HenanAges 18–65 - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT06539481RecruitingPhase 4
ILUVIEN eye implant for kids with recurrent eye inflammation
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
BerlinAges 6–17 - NCT05994690RecruitingPhase 3
Newly diagnosed pediatric AML trial with extra treatment options
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
Utrecht, UtrechtAges 1 day–18 years - NCT06294613Recruiting
Robotic surgery for vitreoretinal diseases
This trial tests a robotic system for eye surgery to treat conditions like vitreous hemorrhage or macular pucker. It may help patients who need a procedure called vitrectomy under general anesthesia.
Ghent, East FlandersAges 18–85
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.